Efficacy and safety of alisporivir for the treatment of hepatitis C infection
C Stanciu, A Trifan, C Muzica… - Expert Opinion on …, 2019 - Taylor & Francis
ABSTRACT Introduction: Alisporivir (ALV)(previously known as Debio 025) is a potent,
pangenotypic host-targeting antiviral oral agent acting on cyclophilin A, which is necessary …
pangenotypic host-targeting antiviral oral agent acting on cyclophilin A, which is necessary …
Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis C infection treated with direct-acting antivirals therapy who …
Chronic hepatitis C virus (HCV) infection induces hepatic steatosis due to viral and host
factors. However, information regarding the effects of direct-acting antivirals (DAAs) therapy …
factors. However, information regarding the effects of direct-acting antivirals (DAAs) therapy …
Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥ 65 years old): A systematic review and meta‐analysis
Direct‐acting agents (DAAs) have launched a new era of hepatitis C virus (HCV) treatment.
As aged individuals comprise a large percentage of HCV‐infected patients, the effectiveness …
As aged individuals comprise a large percentage of HCV‐infected patients, the effectiveness …
Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian …
AR Buonomo, R Scotto, C Coppola, B Pinchera… - Medicine, 2020 - journals.lww.com
The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection
is ascertained. However, some authors raised the issue of an increased incidence of de …
is ascertained. However, some authors raised the issue of an increased incidence of de …
Modeling the puzzle of hepatitis C epidemiology in Romania: A pathway to control
H Lopes, R Baptista-Leite, D Franco… - … and Liver Diseases, 2020 - repositorio.ucp.pt
Background & Aims: To combat hepatitis C virus (HCV) and achieve its elimination by 2030,
the emphasis should be on public health policies. In this study, we investigated the …
the emphasis should be on public health policies. In this study, we investigated the …
[PDF][PDF] Effectiveness of 8-and 12-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve HCV Patients in a Real-Life Setting in …
A Trifan, C Stanciu, L Iliescu, I Sporea… - … of Gastrointestinal & …, 2021 - academia.edu
ABSTRACT Background & Aims: The 12-week regimen of ombitasvir/paritaprevir/ritonavir
and dasabuvir (OPrD) has shown high efficacy and tolerability in clinical trials for the …
and dasabuvir (OPrD) has shown high efficacy and tolerability in clinical trials for the …
[HTML][HTML] Impact of Treatment with Direct Antivirals on Coagulation Parameters in Patients with Hepatitis C Virus-Related Liver Cirrhosis and Sustained Virological …
L Huiban, C Stanciu, CM Muzica, I Girleanu, R Avram… - Medicina, 2024 - mdpi.com
Background and Objectives: Sustained virologic responses (SVRs) lead to a decrease in
portal hypertension, the regression of fibrosis, and the improvement in the hepatic synthesis …
portal hypertension, the regression of fibrosis, and the improvement in the hepatic synthesis …
[HTML][HTML] Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis
H Xia, Y Zhang, SD Zaongo, J Liang… - Annals of …, 2021 - ncbi.nlm.nih.gov
Background This study compared the efficacy and tolerability of available direct-acting
antiviral (DAA) regimens between individuals aged 60 years and older and younger patients …
antiviral (DAA) regimens between individuals aged 60 years and older and younger patients …
[PDF][PDF] Efficacy of the “first wave” direct acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort
I Gentile, AR Buonomo, C Coppola, L Staiano… - New …, 2019 - newmicrobiologica.org
Recently, interferon-free therapies became available, and therapeutic strategies now
include a combination of two or three drugs with different mechanisms of action (ie, NS3/4A …
include a combination of two or three drugs with different mechanisms of action (ie, NS3/4A …
Hepatitis C direct‐acting antiviral outcomes in patients 75 years and older
P Parmar, SD Shafran, SM Borgia, K Doucette… - JGH …, 2021 - Wiley Online Library
Abstract Background and Aim Elderly patients with hepatitis C virus (HCV) infection have
worse interferon‐based treatment outcomes than young patients. Direct‐acting antiviral …
worse interferon‐based treatment outcomes than young patients. Direct‐acting antiviral …